tirzepatide surpass 4 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial tirzepatide for ckd SURPASS-4: slows

2 After matching women for age, BMI, breast density, race, ethnicity, and diabetes history, GLP-1 use remained associated with reduced rate of breast cancer

In clinical practice, factors such as fibrosis stage, BMI level, metabolic comorbidities, tolerability (pruritus vs

Each option has distinct mechanisms, effectiveness profiles, and practical considerations

Buffer A consisted of 20 mM ammonium carbonate in water with 0.1% ammonium hydroxide, while buffer B was 100% acetonitrile

Imagine spending weeks or even months on a study, only to discover your results are skewed because the compound you were testing had partially degraded